SEATTLE GENETICS INC's ticker is SGENXXXX and the CUSIP is 812578102. A total of 197 filers reported holding SEATTLE GENETICS INC in Q1 2016. The put-call ratio across all filers is 1.21 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2020 | $9,108,000 | -13.6% | 78,943 | -14.4% | 0.10% | +10.5% |
Q4 2019 | $10,540,000 | +17.6% | 92,245 | -12.1% | 0.09% | +1.2% |
Q3 2019 | $8,966,000 | +184.2% | 104,985 | +130.3% | 0.08% | +174.2% |
Q2 2019 | $3,155,000 | -5.5% | 45,585 | 0.0% | 0.03% | -13.9% |
Q1 2019 | $3,339,000 | +65.5% | 45,585 | +28.0% | 0.04% | +33.3% |
Q4 2018 | $2,018,000 | -63.0% | 35,622 | -49.7% | 0.03% | -56.5% |
Q3 2018 | $5,457,000 | -86.0% | 70,758 | -88.0% | 0.06% | -86.8% |
Q2 2018 | $39,015,000 | -23.4% | 587,657 | -39.6% | 0.47% | -28.7% |
Q1 2018 | $50,947,000 | -2.8% | 973,379 | -0.6% | 0.66% | -5.2% |
Q4 2017 | $52,398,000 | -5.2% | 979,393 | -3.6% | 0.70% | -7.5% |
Q3 2017 | $55,285,000 | +0.6% | 1,016,090 | -4.3% | 0.75% | -2.0% |
Q2 2017 | $54,958,000 | -54.8% | 1,062,188 | -45.1% | 0.77% | -57.3% |
Q1 2017 | $121,627,000 | -15.5% | 1,934,882 | -29.1% | 1.79% | -17.6% |
Q4 2016 | $143,999,000 | -6.3% | 2,728,810 | -4.1% | 2.18% | -4.9% |
Q3 2016 | $153,653,000 | +33.0% | 2,844,908 | -0.5% | 2.29% | +29.4% |
Q2 2016 | $115,515,000 | +19.9% | 2,858,565 | -0.2% | 1.77% | +20.1% |
Q1 2016 | $96,346,000 | -26.3% | 2,864,018 | -1.7% | 1.47% | -18.4% |
Q4 2015 | $130,803,000 | +14.6% | 2,914,497 | -1.5% | 1.80% | +18.2% |
Q3 2015 | $114,149,000 | -22.3% | 2,960,284 | -2.4% | 1.53% | -4.6% |
Q2 2015 | $146,847,000 | +20.0% | 3,034,022 | -12.4% | 1.60% | +26.0% |
Q1 2015 | $122,408,000 | +6.6% | 3,462,749 | -3.1% | 1.27% | +6.6% |
Q4 2014 | $114,854,000 | -5.2% | 3,574,655 | +9.7% | 1.19% | -6.1% |
Q3 2014 | $121,179,000 | +11.4% | 3,259,240 | +14.6% | 1.27% | +20.1% |
Q2 2014 | $108,758,000 | +11.2% | 2,843,347 | +32.5% | 1.06% | +11.5% |
Q1 2014 | $97,795,000 | +13.5% | 2,146,505 | -0.6% | 0.95% | +12.1% |
Q4 2013 | $86,181,000 | -8.5% | 2,160,469 | +0.5% | 0.85% | -13.4% |
Q3 2013 | $94,185,000 | +36.3% | 2,148,869 | -2.2% | 0.98% | +29.1% |
Q2 2013 | $69,102,000 | – | 2,196,501 | – | 0.76% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Baker Brothers Advisors | 51,049,760 | $3,738,884,000 | 23.93% |
Lagoda Investment Management, L.P. | 76,873 | $5,630,000 | 7.16% |
Matrix Capital Management Company, LP | 3,141,852 | $230,109,000 | 6.14% |
DOMINI IMPACT INVESTMENTS LLC | 3,120 | $229,000 | 3.51% |
Opus Point Partners Management, LLC | 17,832 | $1,306,000 | 1.77% |
Capital International Sarl | 188,200 | $13,784,000 | 1.72% |
EMORY UNIVERSITY | 33,368 | $2,444,000 | 1.72% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 60,900 | $4,460,000 | 1.65% |
CAPITAL GUARDIAN TRUST CO | 1,358,254 | $99,415,000 | 1.32% |
Rhenman & Partners Asset Management AB | 150,598 | $11,030,000 | 1.29% |